

Cell Reports, Volume 40




Supplemental information

**Multiplexed LNP-mRNA vaccination
against pathogenic coronavirus species**

Lei Peng, Zhenhao Fang, Paul A. Renauer, Andrew McNamara, Jonathan J. Park, Qianqian Lin, Xiaoyu Zhou, Matthew B. Dong, Biqing Zhu, Hongyu Zhao, Craig B. Wilen, and Sidi Chen

1 Supplemental information
 2
 3
 4


Figure S1



5
 6 **Figure S1 | Sequence alignment, functional validation and ELISA titration curves for engineered mRNA-**
 7 **encoded spike proteins of three pathogenic human coronavirus species.**
 8 (A) Sequence alignment of spikes of SARS-CoV-2 Delta variant, SARS-CoV and MERS-CoV used in the LNP-
 9 mRNA vaccine. The full-length spike sequences of these three pathogenic human coronavirus species were aligned
 10 and their degree of identity at each residue was color coded by a gradient blue color.


1 **(B-C)** Surface expression of functional spike proteins in 293T cells after electroporation of corresponding mRNA,
2 as detected by human ACE2 **(B)** or human DPP4 **(C)** Fc fusion protein bound to PE anti-Fc antibody.
3 **(D-E)** ELISA titration curves over serial log₁₀-transformed dilution points of plasma samples from mice treated
4 with spike antigens of SARS2 WT/WA1, SARS2 Delta, SARS and MERS. RBD and ECD ELISA spike antigens
5 were used to evaluate the potency of binding antibodies induced by LNP-mRNA vaccines (top and bottom four
6 panels, respectively). The mice were intramuscularly injected with two doses (x2, 2 weeks apart) of the following:
7 **(D)** PBS, 1µg SARS-CoV-2 Delta variant LNP-mRNA (delta), 1µg or 3µg equal mass mixtures (Delta, SARS and
8 MERS mRNA) delivered by LNP (Triplex-CoV); **(E)** PBS, 3µg MERS LNP-mRNA, 3µg equal mass mixture of
9 MERS mRNA in combination with SARS or Delta mRNA delivered by LNP (Comb).
10 **Related to: Figures 1-3**

Figure S2



1
 2 **Figure S2 | Single cell transcriptomics visualization, clustering and cell type identification.**
 3 (a) UMAP visualization, colored by the scaled expression of representative cell type-specific markers in T cells, NK
 4 cells, myeloid cells, B cells, and plasma cells.
 5 (b) Bubble plots showing cell population clusters and their respective feature markers.
 6 (c) UMAP clustering, color-coded by major immune cell populations.
 7 (d) UMAP visualizations of sub-clustering, performed in pooled B cells, plasma cells, myeloid cells, and activated
 8 CD4 T cells. Cell subclusters were identified as the indicated immune populations using the markers presented in
 9 the main Figures.
 10 **Related to: Figure 4**


Figure S3




1
 2 **Figure S3 | Additional pathway analysis of differentially expressed genes compared between vaccination**
 3 **groups in different cell types in the single cell RNA-seq data.**
 4 (A) Bubble plots of overall biological process pathways of differentially expressed genes compared between
 5 vaccination groups in different cell types.
 6 Each dot is a pathway presented with a color and size that represent the respective log fold change and $-\log_{10}$
 7 adjusted p value, while the dot position compares the activation score (mean expression log fold change of pathway
 8 genes) in the analysis of mixCoV-vs-PBS (y axis), relative to the Delta-vs-PBS (x-axis).
 9 (B) Network plots of enriched pathways of differentially expressed genes between the vaccination groups and PBS,
 10 in different cell types.
 11 Each dot is a pathway with the size and color representing the $-\log_{10}$ adjusted p value and the pathway cluster,
 12 respectively. Clusters are labeled with the most significantly enriched member pathway (meta-pathway). Colored
 13 representative meta-pathway clusters correspond to the colored text boxes.
 14 **Related to: Figure 4**

Figure S4


A



B



C




1
2 **Figure S4 | Differential expression, pathway signature and gene set cluster analyses of single cell**
3 **transcriptomics for animals vaccinated by multiplexed LNP-mRNAs.**
4 (A) Square plots compare differential expression (DE) of mixCoV-vs-PBS (y axis) to Delta-vs-PBS (x axis)
5 analyses (n = 3, one independent experiment). Each gene is presented by a dot, positioned by the $\log_2(x+1)$ fold
6 change in either DE analysis and sized by the $-\log_{10}$ FDR-adjusted p value. Genes that are upregulated or down
7 regulated in mixCoV-vs-PBS are shown as red or blue dots, respectively. Analyses were done for B cell, CD4 T cell
8 and CD8 T cell populations.
9 (B) Ridge density plots showing the expression log fold change meta-pathway genes between different vaccination
10 groups in different cell types. Each plot presents the top five meta-pathways in either mixCoV-vs-PBS analysis, and
11 only differentially expressed genes of either analysis were selected for each meta-pathway ridgeplot.
12 (C) Heatmaps of differentially expressed genes between different vaccination groups of representative pathways in
13 different cell types.

14 **Notes:**


- 1 Each indicated cell type in the analysis represents the pooled activated immune cell subsets from the overall UMAP:
- 2 B cell = activated B cells, switched memory B cells, and unswitched memory B cells; CD4 T cells = Th1, Th2 and
- 3 Treg; CD8 T cells = CD8 effector T cells, CD8 TEM, and CD8 TCM.
- 4 **Related to: Figure 4**
- 5

Figure S5




1
 2 **Figure S5 | Analyses of antibody responses induced by sequential and Triplex LNP-mRNA vaccinations.**
 3 (A-B) ELISA OD450 titration curves over serial log₁₀-transformed dilution points of plasma from mice treated with
 4 PBS, sequential or mixture LNP-mRNA vaccinations. ELISA antibody titers are against RBDs or ECDs of SARS2
 5 WT/WA1, SARS2 Delta, SARS and MERS.
 6 The Sequential vaccination mice were intramuscularly injected with two doses (x2, 3 weeks between prime and
 7 boost) of 1 µg SARS-CoV-2 Delta, MERS, SARS LNP-mRNA, three weeks apart, in this sequence (Sequential
 8 Delta-MERS-SARS). The Mixture vaccination mice were intramuscularly injected with two doses (3 weeks between
 9 prime and boost) 3µg equal mass mixture (1µg each) of Delta, SARS and MERS LNP-mRNA (Mixture
 10 Delta/MERS/SARS).
 11 (C-D) Comparative analyses of antibody responses induced by Triplex LNP-mRNA vaccination against SARS-
 12 CoV-2 Delta, SARS-CoV and MERS-CoV *in vivo*. ELISA antibody titers are against (C) RBDs or (D) ECDs of
 13 SARS2 WT/WA1, SARS2 Delta, SARS and MERS.
 14 **Related to: Figure 5**

Figure S6



1
 2 **Figure S6 | Correlation analysis of neutralization datasets; Blocking ELISA titration curves.**
 3 (A) Heatmap of antibody titers of individual mice (one column represents one mouse) against eight spike antigens in
 4 ELISA (one row represents one antigen).
 5 (B) Correlation of antibody titers against RBD (y value) and ECD (x value) of same coronavirus spike, by individual
 6 mouse, or by averaged group.
 7 (C) Correlation of neutralization IC_{50} vs. antibody titers against ECD of same coronavirus spike, by individual
 8 mouse, or by averaged group.
 9 (D) Blocking ELISA titration curve in response to the Delta, SARS or MERS ECD antigen in the presence of
 10 various competing agents or blockers: PBS, Delta ECD, SARS ECD and MERS ECD.
 11 **Related to: Figure 5**

Figure S7



1
 2 **Figure S7 | Blocking ELISA antibody titers of plasma from different vaccination groups.**
 3 **(A)** Blocking ELISA antibody titers against Delta, SARS, and MERS ECDs in the presence of competing reagents
 4 including PBS (negative control), Delta, SARS or MERS ECDs. Statistical significance was analyzed between
 5 different vaccination groups in the presence of the same blocker. PBS plasma group was excluded in the statistical
 6 analysis in order to simplify graph.
 7 **(B)** Normalized blocking effect induced by different blockers in each vaccination group in response to ELISA
 8 antigens of Delta, SARS and MERS ECDs. The blocking effect was quantified by normalizing the blocker-induced
 9 AUC reduction with vaccine-specific AUC increase. The vaccine-specific AUC increase (100%) is calculated from
 10 AUC difference in PBS plasma group (0% or baseline) and vaccination group under the same antigen and blocker
 11 condition. The blocker-induced AUC reduction is the AUC difference between PBS and blocker treatment under the
 12 same vaccination and antigen condition.

13 **Related to: Figure 5**

14
 15

1 **Supplemental Source Data and Statistics**

2 Supplemental excel file(s) contains all original data and statistics for non-NGS experiments.

3

4 **Supplemental Datasets**

5 **Dataset 1 | Single cell GEX of multiplexed LNP-mRNA vaccinated animals**

6 Tabs in this dataset:

- 7 - Metadata of merged single cell GEX dataset.
- 8 - Clustering of scGEX dataset.
- 9 - Two-dimensional UMAP embeddings.
- 10 - Wilcoxon statistics for cluster-specific differentially expressed genes
- 11 - Markers for clustering immune cell subsets.
- 12 - Statistics for cell type proportions across treatment groups.
- 13 - Results of the differential expression (DE) analyses of treatment vs PBS groups in different cell types.
- 14 - Results of the differential expression (DE) analyses of mixCoV vs Delta treatment groups in different cell types.
- 15 - Results of the gProfiler pathway analysis in different comparisons.
- 16